GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » HeartSciences Inc (NAS:HSCS) » Definitions » LT-Debt-to-Total-Asset

HSCS (HeartSciences) LT-Debt-to-Total-Asset : 0.06 (As of Oct. 2024)


View and export this data going back to 2022. Start your Free Trial

What is HeartSciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. HeartSciences's long-term debt to total assests ratio for the quarter that ended in Oct. 2024 was 0.06.

HeartSciences's long-term debt to total assets ratio declined from Oct. 2023 (0.21) to Oct. 2024 (0.06). It may suggest that HeartSciences is progressively becoming less dependent on debt to grow their business.


HeartSciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for HeartSciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HeartSciences LT-Debt-to-Total-Asset Chart

HeartSciences Annual Data
Trend Apr20 Apr21 Apr22 Apr23 Apr24
LT-Debt-to-Total-Asset
0.26 1.35 2.13 0.32 0.05

HeartSciences Quarterly Data
Apr20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.04 0.05 0.11 0.06

HeartSciences LT-Debt-to-Total-Asset Calculation

HeartSciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Apr. 2024 is calculated as

LT Debt to Total Assets (A: Apr. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Apr. 2024 )/Total Assets (A: Apr. 2024 )
=0.434/9.503
=0.05

HeartSciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Oct. 2024 is calculated as

LT Debt to Total Assets (Q: Oct. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Oct. 2024 )/Total Assets (Q: Oct. 2024 )
=0.426/7.777
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HeartSciences  (NAS:HSCS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


HeartSciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of HeartSciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


HeartSciences Business Description

Traded in Other Exchanges
N/A
Address
550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
Executives
David R. Wells director 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent director 750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz director, officer: See Remarks 3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson director, officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092